[go: up one dir, main page]

WO2025114430A1 - Composition à libération modifiée - Google Patents

Composition à libération modifiée Download PDF

Info

Publication number
WO2025114430A1
WO2025114430A1 PCT/EP2024/083905 EP2024083905W WO2025114430A1 WO 2025114430 A1 WO2025114430 A1 WO 2025114430A1 EP 2024083905 W EP2024083905 W EP 2024083905W WO 2025114430 A1 WO2025114430 A1 WO 2025114430A1
Authority
WO
WIPO (PCT)
Prior art keywords
dydrogesterone
composition
pharmaceutically acceptable
acceptable salt
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/083905
Other languages
English (en)
Inventor
Christopher RUPP
Andreas Körner
Sandra HILLMER
Frithjof Sczesny
Heike DINTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Abbott Laboratories GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories GmbH filed Critical Abbott Laboratories GmbH
Publication of WO2025114430A1 publication Critical patent/WO2025114430A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Definitions

  • the present invention relates to a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers.
  • the present invention also relates to a method of manufacturing a modified release composition and a method of treating infertility and/or preventing miscarriages using a modified release composition.
  • Dydrogesterone also known as isopregnenone, dehydroprogesterone, didrogesteron, 6- dehydro-9p,10a-progesterone, or 9p,10a-pregna-4,6-diene-3, 20-dione, is a progestin or a synthetic progestogen, which has the following formula:
  • the present invention seeks to overcome this problem by providing a modified release composition comprising dydrogesterone which is administered in a single dose to improve patient compliance. Moreover, a further aim of the present invention is to provide a modified release composition which would allow the active ingredient to have the desired release profile e.g. release of dydrogesterone over an extended period of time but with a fast onset.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 20% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • the composition may provide a mean dydrogesterone plasma AUC ⁇ o-24h) value relative to that of an immediate release formulation comprising dydrogesterone, of at least about 1.0, or at least about 1.05, or at least about 1.1 , or at least about 1.2, or at least about 1.3, or at least about 1.4, or at least about 1 .5, or at least about 2.0, or at least about 2.5, or at least about 3.0, where the AUC(o-24h) values may be determined under similar conditions.
  • composition may comprise dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of 10% to 40%; one or more release controlling polymers in an amount of 20 to 60%; and one or more pharmaceutically acceptable excipients.
  • the composition may comprise dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of 10% to 40%; one or more release controlling polymers in an amount of 20 to 60%; one or more fillers in an amount of 20% to 65%; and one or more lubricants and/or glidants in an amount of 0.1 % to 10%.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between 1 :6 and 2:1.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between 1 :6 and 2:1.
  • the weight ratio between the filler and the one or more release controlling polymers may be between 1 :3 and 5:2.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of 10% to 40%, preferably 15% to 35%, by weight based on the total weight of the composition.
  • the composition may comprise 15 to 50 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the one or more release controlling polymers may be present in an amount of 20 to 60%, preferably 30 to 40% by weight based on the total weight of the composition.
  • the one or more release controlling polymers may be hydroxypropyl methylcellulose.
  • the filler may be present in an amount of 20% to 65%, preferably 30% to 60%, by weight based on the total weight of the composition.
  • the filler may be lactose, and more preferably lactose monohydrate.
  • the composition may provide a mean dydrogesterone plasma AUC(o-24h) of about 10 to about 25 ng*hr/mL.
  • composition may provide a mean dydrogesterone plasma AUC(o-24h) equivalent to 3 immediate release formulations each comprising 10 mg of dydrogesterone.
  • the composition may provide a mean dydrogesterone plasma AUC(o-24h) of about 10 to about 70 ng*hr/mL.
  • the composition may be free from floating agents and/or gas-generating agents.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, one or more release controlling polymers, and one or more pharmaceutically acceptable excipients, the method comprising the steps of:
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • a method of treating infertility and/or preventing miscarriages using a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, one or more release controlling polymers and one or more pharmaceutically acceptable excipients.
  • the composition may be used in the treatment of gynaecological disorders, menstrual disorders, infertility, prevention of miscarriages, as part of in vitro fertilisation (IVF) treatment or as a component of menopausal hormone therapy.
  • IVF in vitro fertilisation
  • composition may be used in the treatment of endometriosis or as part of in vitro fertilisation (IVF) treatment.
  • IVF in vitro fertilisation
  • composition may be administered once daily.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, and one or more release controlling polymers, and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 20% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • modified release refers to the release of a drug over an extended period of time for example, from about 2 hours to about 24 hours, from about 2 hours to about 16 hours, from about 2 hours to about 12 hours, from about 2 hours to about 10 hours, from about 2 hours to about 7 hours, from about 2 hours to about 6 hours, from about 2 hours to about 5 hours, and from about 2 hours to about 4.5 hours.
  • modified release includes but is not limited to extended release, sustained release, controlled release, delayed release and combinations thereof.
  • 20-30% of the drug is released over a period of about 0.5 to about 2 hours, 50-90% of the drug is released over about 1 to about 3 hours and 80-100% of the drug is released over about 2 to about 4.5 hours.
  • 15-70% of the drug is released over a period of about 0.5 to about 2 hours, 35-90% of the drug is released over about 1 to about 3 hours and 80- 100% of the drug is released over about 2.5 to about 4 hours.
  • the release of dydrogesterone may be identified based on dissolution apparatus 1 of USP (basket), using 600 ml of dissolution medium 0.3% Sodium Laurylsulfate in water with a stir rate of 150 rpm.
  • immediate release refers to the release of a drug over a period of time less than 2 hours, for example less than 1 hour, or less than 45 minutes.
  • immediate release may also be referred to as instant release.
  • the dydrogesterone may be provided in the composition in a free form or as a pharmaceutically acceptable salt.
  • salt refers to a salt of dydrogesterone that is derived from suitable inorganic and organic acids and bases.
  • examples of salts of a basic group include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as trifluoroacetic acid, acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persul
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (CI-C4 alkyl)4 salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate.
  • dydrogesterone may exist in an unsolvated form as well as the solvated form, including the hydrated form.
  • “Hydrate” refers to a complex formed by combination of water molecules with molecules or ions of the solute.
  • Solvate refers to a complex formed by combination of solvent molecules with molecules or ions of the solute.
  • the solvent may be an organic compound, an inorganic compound, or a mixture of both. Solvate is meant to include hydrate.
  • solvents include, but are not limited to, methanol, acetonitrile, N,N- dimethylformamide, tetra hydrofuran, dimethylsulfoxide, and water.
  • the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 10% to about 40%, preferably about 15% to about 40%, preferably about 15% to about 35%, preferably about 16% to about 35%, preferably about 17% to about 34%, preferably about 18% to about 33%, and preferably about 18% to about 32%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21 %, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition.
  • the modified release composition according to the present invention may comprise about 10 mg or more, preferably greater than 10 mg, preferably about 15 to about 40 mg, preferably about 20 to about 40 mg, preferably about 20 to about 30 mg and preferably about 20 mg or about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the composition may comprise about 10 mg, about 15 mg, about 20 mg, about 30 mg or about 40 mg, of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • any dosages should be taken as referring to the amount of dydrogesterone in free base form.
  • a reference to “20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof” means an amount of dydrogesterone or a pharmaceutically acceptable salt thereof which provides the same amount of dydrogesterone as 20 mg of dydrogesterone free base.
  • the modified release composition further comprises one or more release controlling polymers.
  • release controlling polymer refers to any polymer material suitable for pharmaceutical dosage forms that retard the release of drug substances from such dosage forms. Examples of suitable release controlling polymers can be found in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990.
  • Suitable release controlling polymers include hydrophilic or hydrophobic polymers comprising one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, xanthan gum, gellan gum, shellac, rosin, zein (prolamine from corn), povidone, kollidon SR (polyvinyl acetate and povidone), a poly(meth)acrylate, poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, polyethylene oxide, carbomer homopolymer, hydroxyprop
  • the modified release composition may contain more than one type of release controlling polymer.
  • the modified release composition may contain two different types of release controlling polymers.
  • the term “different type” refers to polymers that can be distinguished by any chemical or physical property. The two or more polymers may differ by their molecular weight, chemical structure, release profile or grade.
  • the modified release composition may contain two different types of release controlling polymers that differ by their release profile or grade.
  • the modified release composition may contain two different types of hydroxypropyl methyl cellulose (hypromellose) polymers, for example, a combination of methocel K15M and methocel E15LV.
  • the one or more release controlling polymers may be present in an amount of about 20% to about 60%, preferably about 25% to about 60%, preferably about 25% to about 55%, preferably about 28% to about 50%, preferably about 30% to about 40%, preferably about 30% to about 35%, or preferably about 25% to about 35%, by weight based on the total weight of the composition.
  • one or more release controlling polymers may be present in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about
  • modified release composition comprises two or more release controlling polymers
  • weight percentages specified herein refers to the total amount of release controlling polymers present in the modified release composition.
  • the modified release composition according to the present invention further contains one or more pharmaceutically acceptable carriers or excipients.
  • Pharmaceutically acceptable carriers or excipients may include fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • Suitable fillers/diluents include, starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, and combinations thereof.
  • the filler is preferably lactose, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 20% to about 65%, preferably about 20% to about 60%, preferably about 25% to about 60%, preferably about 30% to about 60%, preferably about 30% to about 55%, and preferably about 30% to about 50%, by weight based on the total weight of the composition.
  • the one or more fillers may be present in an amount of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51 %, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59% or about 60%, by weight based on the total weight of the composition.
  • Suitable binders include, microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K30 or PVP 90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropyl cellulose, copovidone, and combinations thereof.
  • the binder may be present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1% to about 10%, by weight based on the total weight of the composition.
  • Suitable lubricants/glidants include, zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • the lubricant/glidant is preferably colloidal anhydrous silica and/or magnesium stearate, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1% to about 10%, preferably about 0.5% to about 5%, and preferably about 1% to about 3%, by weight based on the total weight of the composition.
  • Suitable disintegrants include, carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g.
  • crospovidone polyplasdone XL or kollidon CL
  • croscarmellose sodium sodium starch glycolate
  • polacrillin potassium low substituted hydroxypropyl cellulose
  • alginic acid sodium alginate and guar gum
  • crosslinked PVP crospovidone
  • crosslinked CMC Ac-Di-Sol
  • carboxymethyl starch-Na pirimojel and explotab
  • the disintegrant may be present in an amount of about 0.01 % to about 15%, preferably about 0.05% to about 12%, and preferably about 0.1% to about 10%, by weight based on the total weight of the composition.
  • Suitable plasticizers include, propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • the plasticizer may be present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • the modified release composition according to the present invention may provide a mean dydrogesterone plasma AUC(o-24h) value relative to that of an immediate release formulation comprising dydrogesterone, of at least about 1.0, or at least about 1.05, or at least about 1.1 , or at least about 1.2, or at least about 1.3, or at least about 1.4, or at least about 1.5, or at least about 2.0, or at least about 2.5, or at least about 3.0, where the AUC(o-24h) values may be determined under similar conditions.
  • the composition may provide a mean dydrogesterone plasma AUC(o-24h) value relative to that of commercially available Duphaston® tablets of at least about 1.0, or at least about 1 .05, or at least about 1.1 , or at least about 1.2, or at least about 1.3, or at least about 1.4, or at least about 1.5, or at least about 2.0, or at least about 2.5, or at least about 3.0, where the AUC(o-24h) values may be determined under similar conditions.
  • the modified release composition according to the present invention may provide a mean dydrogesterone plasma AUC(o-24h) equivalent to at least two immediate release formulations each comprising 10 mg of dydrogesterone.
  • AUG as used herein means area under the plasma concentration-time curve, as calculated by the trapezoidal rule over a time interval (e.g. complete 24-hour interval); and signifies the extent of the absorption of a drug.
  • Cmax as used herein means the highest plasma concentration of the drug attained within the dosing interval (e.g., 24 hours).
  • modified release composition may provide a mean dydrogesterone plasma AUC(o-24h) equivalent to 2 to 4 immediate release formulations each comprising 10 mg of dydrogesterone.
  • the modified release composition may provide a mean dydrogesterone plasma AUC(o-24h) equivalent to 2, 3 or 4 immediate release formulations each comprising 10 mg of dydrogesterone.
  • the modified release composition may provide a mean dydrogesterone plasma AUC ⁇ o- 24h) equivalent to 2 or 3 immediate release formulations each comprising 10 mg of dydrogesterone.
  • each immediate release formulation comprising 10 mg of dydrogesterone may provide a mean dydrogesterone plasma AUC(o-24h) of about 4 to about 25 ng*hr/mL, preferably about 6 to about 20 ng*hr/mL, preferably about 7 to about 18 ng*hr/mL and preferably about 8 to about 15 ng*hr/mL.
  • the Cmax and AUC(o-24h) are calculated using a non-compartmental analysis model using Phoenix® WinNonlin® - Software, Version 8.3.5 (Certara USA, Inc.) for analysis of Dydrogesterone and Dihydrodydrogesterone.
  • the immediate release formulation comprising 10 mg of dydrogesterone may be any commercially available immediate release product containing 10 mg of dydrogesterone, such as Duphaston®.
  • the modified release composition according to the present invention may provide a mean dydrogesterone plasma AUC ⁇ o-24h) equivalent to two immediate release formulations each comprising 10 mg of dydrogesterone, such as Duphaston®.
  • the modified release composition according to the present invention may provide a mean dydrogesterone plasma AUC ⁇ o-24h) equivalent to three immediate release formulations each comprising 10 mg of dydrogesterone, such as Duphaston®.
  • the modified release composition may be free from floating agents.
  • floating agents may include sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • the modified release composition may be free from gas-generating agents.
  • gas-generating agents may include carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 1 :6 and about 2:1 , preferably between about 1 :4 and about 3:2, preferably between about 1 :2 and about 4:3 and preferably between about 1 :2 and about 1 :1.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 1 :6 and about 2:1 , preferably between about 1 :4 and about 3:2, preferably between about 1 :3 and about 2:1 , and preferably between about 1 :3 and about 1 :1.
  • the weight ratio between the filler and the one or more release controlling polymers may be between about 1 :3 and about 5:2, preferably between about 1 :2 and about 7:3, preferably between about 3:4 and about 2:1 , and preferably between about 4:5 and about 5:3.
  • the modified release composition according to the present invention may be formulated as a single dosage form, preferably as a single tablet, and more preferably as a single oral tablet.
  • the modified release composition according to the present invention may be manufactured by a granulation process.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the one or more release controlling polymers may be present in an amount of about 25% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the one or more release controlling polymers may be present in an amount of about 25% to about 35% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 1 :6 and about 2: 1.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the one or more fillers may be present in an amount of about 20% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 1 :6 and about 2:1.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between the filler and the one or more release controlling polymers may be between about 1 :3 and about 5:2.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and lactose, wherein lactose may be present in an amount of about 20% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 10% to about 30% by weight based on the total weight of the composition; the one or more release controlling polymers may be present in an amount of about 30% to about 35% by weight based on the total weight of the composition; and the one or more fillers may be present in an amount of about 30% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and lactose, wherein dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 10% to about 30% by weight based on the total weight of the composition; the one or more release controlling polymers may be present in an amount of about 30% to about 35% by weight based on the total weight of the composition; and lactose may be present in an amount of about 30% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising: dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 10% to about 30% by weight based on the total weight of the composition; one or more release controlling polymers in an amount of about 30% to about 35% by weight based on the total weight of the composition; one or more fillers in an amount of about 30% to about 60% by weight based on the total weight of the composition; and one or more lubricants or glidants in an amount of about 0.5% to about 5% by weight based on the total weight of the composition.
  • a modified release composition comprising: dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 10% to about 30% by weight based on the total weight of the composition; one or more release controlling polymers in an amount of about 30% to about 35% by weight based on the total weight of the composition; lactose in an amount of about 30% to about 60% by weight based on the total weight of the composition; silicon dioxide in an amount of about 0.5% to about 2% by weight based on the total weight of the composition; and magnesium stearate in an amount of about 0.5% to about 2% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein 20-30% of dydrogesterone may be released over a period of about 0.5 to about 2 hours, 50-90% of dydrogesterone may be released over about 1 to about 3 hours and 80-100% of dydrogesterone may be released over about 2 to about 4.5 hours.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein 15-70% of dydrogesterone may be released over a period of about 0.5 to about 2 hours, 35-90% of dydrogesterone may be released over about 1 to about 3 hours and 80-100% of dydrogesterone may be released over about 2.5 to about 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 20% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 25% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 25% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 30% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 30% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 35% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 35% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 40% of dydrogesterone in 1 hour and not less than 70% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 50% of dydrogesterone in 1 hour and not less than 70% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 40% of dydrogesterone in 1 hour and not less than 75% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 50% of dydrogesterone in 1 hour and not less than 75% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 40% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 50% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 40% of dydrogesterone in 1 hour and not less than 85% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 50% of dydrogesterone in 1 hour and not less than 85% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 40% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 4 hours.
  • a modified release composition comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more pharmaceutically acceptable excipients, wherein said composition releases not more than 50% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 4 hours.
  • a modified release composition for use in the treatment of endometriosis comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition for use as part of in vitro fertilisation (IVF) treatment comprising, dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition comprising 15 to 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein said composition provides a mean dydrogesterone plasma AUC(o-24h) of 10 to 25 ng*hr/mL.
  • the dydrogesterone may be provided in the composition in a free form or as a pharmaceutically acceptable salt as described herein.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 15% to about 25%, preferably about 16% to about 24%, preferably about 17% to about 23%, preferably about 18% to about 22%, preferably about 19% to about 21 %, and preferably about 20%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21 %, about 22%, about 23%, about 24% or about 25%, by weight based on the total weight of the composition.
  • the modified release composition according to the present invention may comprise about 15 to about 25 mg, preferably about 16 to about 24 mg, preferably about 17 to about 23 mg, preferably about 18 to about 22 mg, preferably about 19 to about 21 mg and preferably about 20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the composition may comprise about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg or about 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the composition comprises 20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the modified release composition further comprises one or more release controlling polymers as described herein.
  • the release controlling polymer is hydroxypropyl methyl cellulose (hypromellose).
  • the one or more release controlling polymers may be present in an amount of about 30% to about 40%, preferably about 31% to about 39%, preferably about 32% to about 38%, preferably about 33% to about 37%, and preferably about 34 to about 36% by weight based on the total weight of the composition. In an embodiment, one or more release controlling polymers may be present in an amount of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition. In the case where the modified release composition comprises two or more release controlling polymers, the weight percentages specified herein refers to the total amount of release controlling polymers present in the modified release composition.
  • the modified release composition may provide a mean dydrogesterone plasma AUC(o-24h) of about
  • the modified release composition may provide a mean dydrogesterone plasma AUC(o-24h) of about 10 ng*hr/mL, preferably about 11 ng*hr/mL, preferably about 12 ng*hr/mL, preferably about 13 ng*hr/mL, preferably about 14 ng*hr/mL, preferably about 15 ng*hr/mL, preferably about 16 ng*hr/mL, preferably about 17 ng*hr/mL, preferably about 18 ng*hr/mL, preferably about 19 ng*hr/mL, preferably about 20 ng*hr/mL, preferably about 21 ng*hr/mL, preferably about 22 ng*hr/mL, preferably about 23 ng*hr/mL, preferably about 24 ng*hr/mL or
  • the modified release composition may provide a mean dydrogesterone plasma C ma x of about 2 to about 5 ng/mL, preferably about 2 to about 4 ng/mL, preferably about 2 to about 3 ng/mL, and preferably about 2.5 to about 3 ng/mL.
  • the modified release composition may provide a mean dydrogesterone plasma C ma x of about 2 ng/mL, preferably about 2.1 ng/mL, preferably about 2.2 ng/mL, preferably about 2.3 ng/mL, preferably about 2.4 ng/mL, preferably about 2.5 ng/mL, preferably about 2.6 ng/mL, preferably about 2.7 ng/mL, preferably about 2.8 ng/mL, preferably about 2.9 ng/mL, preferably about 3.0 ng/mL, preferably about 3.1 ng/mL, preferably about 3.2 ng/mL, preferably about 3.3 ng/mL, preferably about 3.4 ng/mL, preferably about 3.5 ng/mL, preferably about 3.6 ng/mL, preferably about 3.7 ng/mL, preferably about 3.8 ng/mL, preferably about 3.9 ng/mL, preferably about 4.0 ng
  • the modified release composition may provide a mean dihydrodydrogesterone plasma AUC(o-24h) of about 350 to about 750 ng*hr/mL, preferably about 400 to about 700 ng*hr/mL, preferably about 450 to about 650 ng*hr/mL, preferably about 500 to about 600 ng*hr/mL, and preferably about 500 to about 550 ng*hr/mL.
  • the modified release composition may provide a mean dihydrodydrogesterone plasma AUC(o-24h) of about 350 ng*hr/mL, preferably about 360 ng*hr/mL, preferably about 370 ng*hr/mL, preferably about 380 ng*hr/mL, preferably about 390 ng*hr/mL, preferably about 400 ng*hr/mL, preferably about 410 ng*hi7mL, preferably about 420 ng*hr/mL, preferably about 430 ng*hr/mL, preferably about 440 ng*hr/mL, preferably about 450 ng*hr/mL, preferably about 460 ng*hr/mL, preferably about 470 ng*hr/mL, preferably about 480 ng*hr/mL, preferably about 490 ng*hr/mL, preferably about 500 ng*hr/mL, preferably about 360 ng*hr/
  • the modified release composition may provide a mean dihydrodydrogesterone plasma C ma x of about 50 to about 110 ng/mL, preferably about 55 to about 105 ng/mL, preferably about 60 to about 100 ng/mL, preferably about 65 to about 95 ng/mL, preferably about 70 to about 90 ng/mL, and preferably about 75 to about 85 ng/mL.
  • the modified release composition may provide a mean dihydrodydrogesterone plasma C ma x of about 50 ng/mL, preferably about 51 ng/mL, preferably about 52 ng/mL, preferably about 53 ng/mL, preferably about 54 ng/mL, preferably about 55 ng/mL, preferably about 56 ng/mL, preferably about 57 ng/mL, preferably about 58 ng/mL, preferably about 59 ng/mL, preferably about 60 ng/mL, preferably about 61 ng/mL, preferably about 62 ng/mL, preferably about 63 ng/mL, preferably about 64 ng/mL, preferably about 65 ng/mL, preferably about 66 ng/mL, preferably about 67 ng/mL, preferably about 68 ng/mL, preferably about 69 ng/mL, preferably about 70 ng/mL, preferably about 71
  • the AUC(o-24h) and C ma x values provided herein may be measured when a patient is in a fasted state.
  • the “fasted state” as used herein refers to a state where the patient is provided with no food for at least 10 hours prior to dosing.
  • the modified release composition may contain one or more pharmaceutically acceptable carriers or excipients as described herein.
  • Pharmaceutically acceptable carriers or excipients may include fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • the modified release composition preferably comprises lactose as a filler, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 35% to about 55%, preferably about 40% to about 50%, preferably about 41% to about 49%, preferably about 42% to about 48%, and preferably about 43% to about 47%, by weight based on the total weight of the composition.
  • the one or more fillers may be present in an amount of about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55%, by weight based on the total weight of the composition.
  • the modified release composition preferably comprises colloidal anhydrous silica and/or magnesium stearate as the lubricant/glidant, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1% to about 10%, preferably about 0.5% to about 5%, and preferably about 1 % to about 3%, by weight based on the total weight of the composition.
  • the modified release composition may be free from floating agents and/or gas-generating agents as described herein.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 2:5 and about 5:6, preferably between about 2:3 and about 4:5 and preferably between about 1 :2 and about 2:3.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 1 :3 and about 4:5, preferably between about 1 :3 and about 3:5, and preferably between about 2:5 and about 1 :1.
  • the weight ratio between the filler and the one or more release controlling polymers may be between about 9:10 and about 2:1 , preferably between about 1 :1 and about 3:2, and preferably between about 5:4 and about 4:3.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 15% to about 25% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the one or more release controlling polymers may be present in an amount of about 30% to about 40% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 1 :2 and about 2:3.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the one or more fillers may be present in an amount of about 40% to about 50% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 2:5 and about 1 :1.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between the filler and the one or more release controlling polymers may be between about 5:4 and about 4:3.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and lactose, wherein lactose may be present in an amount of about 40% to about 50% by weight based on the total weight of the composition.
  • a modified release composition comprising 15 to 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein 15-70% of dydrogesterone may be released over a period of about 0.5 to about 2 hours, 35-90% of dydrogesterone may be released over about 1 to about 3 hours and 80-100% of dydrogesterone may be released over about 2.5 to about 4 hours.
  • a modified release composition for use in the treatment of endometriosis comprising, 15 to 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition for use as part of in vitro fertilisation (IVF) treatment comprising, 15 to 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition comprising 26 to 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein said composition provides a mean dydrogesterone plasma AUC(o-24h) of 10 to 70 ng*hr/mL.
  • the dydrogesterone may be provided in the composition in a free form or as a pharmaceutically acceptable salt as described herein.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 10% to about 35%, preferably about 15% to about 35%, preferably about 20% to about 35%, preferably about 25% to about 35%, preferably about 28% to about 32%, and preferably about 30%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof may be present in an amount of about 10%, about 11 %, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21 %, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, or about 35%, by weight based on the total weight of the composition.
  • the modified release composition according to the present invention may comprise about 26 to about 35 mg, preferably about 27 to about 34 mg, preferably about 28 to about 33 mg, preferably about 29 to about 32 mg, and preferably about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the composition may comprise about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg or about 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the composition comprises 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the modified release composition further comprises one or more release controlling polymers as described herein.
  • the release controlling polymer is hydroxypropyl methyl cellulose (hypromellose).
  • the one or more release controlling polymers may be present in an amount of about 25% to about 40%, preferably about 26% to about 39%, preferably about 27% to about 38%, preferably about 28% to about 37%, and preferably about 29% to about 36% by weight based on the total weight of the composition. In an embodiment, one or more release controlling polymers may be present in an amount of about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition. In the case where the modified release composition comprises two or more release controlling polymers, the weight percentages specified herein refers to the total amount of release controlling polymers present in the modified release composition.
  • the modified release composition may provide a mean dydrogesterone plasma AUC(o-24h) of about 10 to about 70 ng*hr/mL, preferably about 15 to about 65 ng*hr/mL, preferably about 20 to about 60 ng*hr/mL, preferably about 25 to about 55 ng*hr/mL, preferably about 30 to about 50 ng*hr/mL, and preferably about 35 to about 45 ng*hr/mL.
  • the modified release composition may provide a mean dydrogesterone plasma AUC(o- 24h) of about 10 ng*hr/mL, preferably about 11 ng*hr/mL, preferably about 12 ng*hr/mL, preferably about 13 ng*hr/mL, preferably about 14 ng*hr/mL, preferably about 15 ng*hr/mL, preferably about
  • 16 ng*hr/mL preferably about 17 ng*hr/mL, preferably about 18 ng*hr/mL, preferably about 19 ng*hr/mL, preferably about 20 ng*hr/mL, preferably about 21 ng*hr/mL, preferably about 22 ng*hr/mL, preferably about 23 ng*hr/mL, preferably about 24 ng*hr/mL, preferably about 25 ng*hr/mL, preferably about 26 ng*hr/mL, preferably about 27 ng*hr/mL, preferably about 28 ng*hr/mL, preferably about 29 ng*hr/mL, preferably about 30 ng*hr/mL, preferably about 31 ng*hr/mL, preferably about 32 ng*hr/mL, preferably about 33 ng*hr/mL, preferably about 34 ng*hr/mL, preferably 35 ng*hr/mL
  • the modified release composition may provide a mean dydrogesterone plasma C ma x of about 1 .5 to about 7.5 ng/mL, preferably about 2 to about 7 ng/mL, preferably about 3 to about 6 ng/mL and preferably about 4 to about 5 ng/mL.
  • the modified release composition may provide a mean dydrogesterone plasma C ma x of about 1.5 ng/mL, preferably about 1.6 ng/mL, preferably about 1.7 ng/mL, preferably about 1.8 ng/mL, preferably about 1.9 ng/mL, preferably about 2.0 ng/mL, preferably about 2.1 ng/mL, preferably about 2.2 ng/mL, preferably about 2.3 ng/mL, preferably about 2.4 ng/mL, preferably about 2.5 ng/mL, preferably about 2.6 ng/mL, preferably about 2.7 ng/mL, preferably about 2.8 ng/mL, preferably about 2.9 ng/mL, preferably about 3.0 ng/mL, preferably about 3.1 ng/mL, preferably about 3.2 ng/mL, preferably about 3.3 ng/mL, preferably about 3.4 ng/mL, preferably about 3.5 ng/
  • the modified release composition may provide a mean dihydrodydrogesterone plasma AUC(o-24h) of about 400 to about 2200 ng*hr/mL, preferably about 500 to about 2000 ng*hr/mL, preferably about 600 to about 1800 ng*hr/mL, and preferably about 700 to about 1500 ng*hr/mL.
  • the modified release composition may provide a mean dihydrodydrogesterone plasma AUC(o-24h) of about 400 ng*hr/mL, preferably about 450 ng*hr/mL, preferably about 500 ng*hr/mL, preferably about 550 ng*hr/mL, preferably about 600 ng*hr/mL, preferably about 650 ng*hr/mL, preferably about 700 ng*hr/mL, preferably about 750 ng*hr/mL, preferably about 800 ng*hr/mL, preferably about 850 ng*hr/mL, preferably about 900 ng*hr/mL, preferably about 950 ng*hr/mL, preferably about 1000 ng*hr/mL, preferably about 1050 ng*hr/mL, preferably about 1100 ng*hr/mL, preferably 1150 ng*hr/mL, preferably about 1200
  • the modified release composition may provide a mean dihydrodydrogesterone plasma C ma x of about 40 to about 200 ng/mL, preferably about 50 to about 175 ng/mL, preferably about 60 to about 150 ng/mL, and preferably about 70 to about 120 ng/mL.
  • the modified release composition may provide a mean dihydrodydrogesterone plasma C ma x of about 40 ng/mL, preferably about 45 ng/mL, preferably about 50 ng/mL, preferably about 55 ng/mL, preferably about 60 ng/mL, preferably about 65 ng/mL, preferably about 70 ng/mL, preferably about 75 ng/mL, preferably about 80 ng/mL, preferably about 85 ng/mL, about 90 ng/mL, preferably about 95 ng/mL, preferably about 100 ng/mL, preferably about 105 ng/mL, preferably about 110 ng/mL, preferably about 115 ng/mL, preferably about 120 ng/mL, preferably about 125 ng/mL, preferably about 130 ng/mL, preferably about 135 ng/mL, preferably about 140 ng/mL, preferably about 145 ng/mL, preferably
  • the AUC(o-24h) and C ma x values provided herein may be measured when a patient is in a fasted state.
  • the “fasted state” as used herein refers to a state where the patient is provided with no food for at least 10 hours prior to dosing.
  • the modified release composition may contain one or more pharmaceutically acceptable carriers or excipients as described herein.
  • Pharmaceutically acceptable carriers or excipients may include fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • the modified release composition preferably comprises lactose as a filler, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 30% to about 65%, preferably about 30% to about 60%, preferably about 30% to about 50%, preferably about 30% to about 45%, and preferably about 30% to about 40%, by weight based on the total weight of the composition.
  • the one or more fillers may be present in an amount of about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41 %, about 42%, about 43%, about 44%, about 45%, about
  • the modified release composition preferably comprises colloidal anhydrous silica and/or magnesium stearate as the lubricant/glidant, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1% to about 10%, preferably about 0.5% to about 5%, and preferably about 1 % to about 3%, by weight based on the total weight of the composition.
  • the modified release composition may be free from floating agents and/or gas-generating agents as described herein.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 1 :4 and about 3:2, preferably between about 2:5 and about 5:4 and preferably between about 1 :2 and about 6:5.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 1 :6 and about 6:5, preferably between about 1 :3 and about 6:5, and preferably between about 1 :2 and about 7:6.
  • the weight ratio between the filler and the one or more release controlling polymers may be between about 3:4 and about 5:2, preferably between about 4:5 and about 5:3, and preferably between about 4:5 and about 4:3.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the one or more release controlling polymers may be present in an amount of about 25% to about 40% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers may be between about 1 :2 and about 6:5.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the one or more fillers may be present in an amount of about 30% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler may be between about 1 :2 and about 7:6.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and one or more fillers, wherein the weight ratio between the filler and the one or more release controlling polymers may be between about 4:5 and about 4:3.
  • a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof; one or more release controlling polymers; and lactose, wherein lactose may be present in an amount of about 30% to about 60% by weight based on the total weight of the composition.
  • a modified release composition comprising 26 to 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein 20-30% of dydrogesterone may be released over a period of about 0.5 to about 2 hours, 50-90% of dydrogesterone may be released over about 1 to about 3 hours and 80-100% of dydrogesterone may be released over about 2 to about 4.5 hours.
  • a modified release composition for use in the treatment of endometriosis comprising, 26 to 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition for use as part of in vitro fertilisation (IVF) treatment comprising, 26 to 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the dydrogesterone in the extended release component and the immediate release component may be provided in the modified release composition in a free form or as a pharmaceutically acceptable salt as described herein.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7% to about 25%, and preferably about 8% to about 20%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7%, about 8%, about 9%, about 10%, about 11 %, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, or about 25%, by weight based on the total weight of the composition.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 1 % to about 15%, and preferably about 2% to about 10%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%, by weight based on the total weight of the composition.
  • the extended release component may comprise about 5 to about 30 mg, and preferably about 10 to about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the immediate release component may comprise about 2 to about 15 mg, preferably about 3 to about 10 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the extended release component further comprises one or more release controlling polymers as described herein.
  • the release controlling polymer is hydroxypropyl methyl cellulose (hypromellose), and in particular hydroxypropyl methyl cellulose having a viscosity greater than 10 mPa-s (10 cps) in 2% water at 20°C.
  • the one or more release controlling polymers in the extended release component may be present in an amount of about 10% to about 40%, preferably about 15% to about 35%, or preferably about 20% to about 35%, by weight based on the total weight of the composition.
  • one or more release controlling polymers may be present in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, or about 35%, by weight based on the total weight of the composition.
  • the immediate release component may further comprise one or more coating polymers or film formers.
  • the one or more coating polymers or film formers in the immediate release component may be present in an amount of about 1 % to about 15%, and preferably about 2% to about 10%, by weight based on the total weight of the composition.
  • one or more coating polymers or film formers may be present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the composition.
  • the one or more coating polymers or film formers in the immediate release component may preferably be hydroxypropyl methyl cellulose (hypromellose) having a viscosity less than 10 mPa-s (10 cps) in 2% water at 20°C (e.g., hypromellose E5) or Opadry TF.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the immediate release component may be between about 1 :1 and about 1 :1.4, preferably between about 1 :1 and about 1 :1.3, preferably between about 1 :1 and about 1 :1.2 and preferably about 1 :1.
  • the immediate release component may consist of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • the extended release component preferably comprises lactose as a filler, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 25% to about 60%, and preferably about 30% to about 55%, by weight based on the total weight of the composition.
  • the one or more fillers may be present in an amount of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55%, by weight based on the total weight of the composition.
  • the extended release component preferably comprises colloidal anhydrous silica and/or magnesium stearate as the lubricant/glidant, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1 % to about 5%, preferably about 0.2% to about 5%, and preferably about 0.5% to about 3%, by weight based on the total weight of the composition.
  • the modified release composition may be free from floating agents and/or gas-generating agents as described herein.
  • the modified release composition according to the present invention may be formulated as a single dosage form, preferably as a single tablet, and more preferably as a single oral tablet.
  • the modified release composition according to the present invention may be manufactured by a granulation process.
  • a modified release composition comprising:
  • an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 7% to about 25% by weight based on the total weight of the composition; one or more release controlling polymers in an amount of about 10% to about 40% by weight based on the total weight of the composition; one or more fillers in an amount of about 30% to about 55% by weight based on the total weight of the composition; and one or more lubricants or glidants in an amount of about 0.2% to about 5% by weight based on the total weight of the composition, and
  • an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 1 % to about 15% by weight based on the total weight of the composition.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the immediate release component is between about 1 :1 and about 1 :1.4.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component consisting of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein 20-65% of dydrogesterone may be released over a period of about 0.25 to about 1 hour, 35-95% of dydrogesterone may be released over about 1 to about 3 hours and 50-100% of dydrogesterone may be released over about 3 to about 5 hours.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein said composition releases greater than 30% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising (a) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, for use as part of in vitro fertilisation (IVF) treatment.
  • IVF in vitro fertilisation
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the dydrogesterone in the extended release component and the immediate release component may be provided in the modified release composition in a free form or as a pharmaceutically acceptable salt as described herein.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7% to about 25%, and preferably about 8% to about 20%, by weight based on the total weight of the composition.
  • dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7%, about 8%, about 9%, about 10%, about 11 %, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%, by weight based on the total weight of the composition.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 1 % to about 15%, and preferably about 2% to about 10%, by weight based on the total weight of the composition. In an embodiment, dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the composition.
  • the extended release component may comprise about 5 to about 30 mg, and preferably about 10 to about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the immediate release component may comprise about 2 to about 15 mg, preferably about 3 to about 10 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the extended release component further comprises one or more release controlling polymers as described herein.
  • the release controlling polymer is hydroxypropyl methyl cellulose (hypromellose), and in particular hydroxypropyl methyl cellulose having a viscosity greater than 10 mPa-s (10 cps) in 2% water at 20°C.
  • the one or more release controlling polymers in the extended release component may be present in an amount of about 10% to about 40%, preferably about 15% to about 35%, or preferably about 20% to about 35%, by weight based on the total weight of the composition. In an embodiment, one or more release controlling polymers may be present in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, or about 35%, by weight based on the total weight of the composition.
  • the outer layer may further comprise one or more coating polymers or film formers.
  • the one or more coating polymers or film formers in the outer layer may be present in an amount of about 1% to about 15%, and preferably about 2% to about 10%, by weight based on the total weight of the composition.
  • one or more binders may be present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the composition.
  • the one or more coating polymers or film formers in the immediate release component may preferably be hydroxypropyl methyl cellulose (hypromellose) having a viscosity less than 10 mPa-s (10 cps) in 2% water at 20°C (e.g., hypromellose E5) or Opadry TF.
  • hydroxypropyl methyl cellulose (hypromellose) having a viscosity less than 10 mPa-s (10 cps) in 2% water at 20°C (e.g., hypromellose E5) or Opadry TF.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the outer layer may be between about 1 :1 and about 1 :1.4, preferably between about 1 :1 and about 1 :1.3, preferably between about 1 :1 and about 1 :1.2 and preferably about 1 :1.
  • the outer layer may consist of an immediate release component consisting of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • the modified release composition may contain one or more pharmaceutically acceptable carriers or excipients as described herein.
  • Pharmaceutically acceptable carriers or excipients may include fillers, diluents, binders, lubricants, glidants, disintegrants, coating polymers or film formers and plasticizers.
  • the extended release component preferably comprises lactose as a filler, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 35% to about 60%, and preferably about 40% to about 55%, by weight based on the total weight of the composition. In an embodiment, the one or more fillers may be present in an amount of about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51 %, about 52%, about 53%, about 54%, or about 55%, by weight based on the total weight of the composition.
  • the extended release component preferably comprises colloidal anhydrous silica and/or magnesium stearate as the lubricant/glidant, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1 % to about 5%, preferably about 0.2% to about 5%, and preferably about 0.5% to about 3%, by weight based on the total weight of the composition.
  • the modified release composition may be free from floating agents and/or gas-generating agents as described herein.
  • the modified release composition according to the present invention may be formulated as a single dosage form, preferably as a single tablet, and more preferably as a single oral tablet.
  • the modified release composition according to the present invention may be manufactured by a granulation process.
  • a modified release composition comprising:
  • a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 7% to about 25% by weight based on the total weight of the composition; one or more release controlling polymers in an amount of about 10% to about 40% by weight based on the total weight of the composition; one or more fillers in an amount of about 35% to about 60% by weight based on the total weight of the composition; and one or more lubricants or glidants in an amount of about 0.2% to about 5% by weight based on the total weight of the composition, and
  • an outer layer over said core wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 2% to about 10% by weight based on the total weight of the composition.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the immediate release component is between about 1:1 and about 1 :1.4.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component consisting of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein 20-65% of dydrogesterone may be released over a period of about 0.25 to about 1 hour, 35-95% of dydrogesterone may be released over about 1 to about 3 hours and 50-100% of dydrogesterone may be released over about 3 to about 5 hours.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein said composition releases greater than 35% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising (a) a core comprising an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers; and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, for use as part of in vitro fertilisation (IVF) treatment.
  • IVF in vitro fertilisation
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the dydrogesterone in the extended release component and the immediate release component may be provided in the modified release composition in a free form or as a pharmaceutically acceptable salt as described herein.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7% to about 25%, preferably about 8% to about 20%, and preferably about 9% to about 17%, by weight based on the total weight of the composition. In an embodiment, dydrogesterone or a pharmaceutically acceptable salt thereof in the extended release component may be present in an amount of about 7%, about 8%, about 9%, about 10%, about 11 %, about 12%, about 13%, about 14%, about 15%, about 16%, or about 17%, by weight based on the total weight of the composition.
  • the dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 2% to about 15%, preferably about 3% to about 10%, and preferably about 5% to about 10%, by weight based on the total weight of the composition. In an embodiment, dydrogesterone or a pharmaceutically acceptable salt thereof in the immediate release component may be present in an amount of about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the composition.
  • the extended release component may comprise about 10 to about 30 mg, preferably about 15 to about 25 mg, preferably about 20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the immediate release component may comprise about 5 to about 15 mg, preferably about 10 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • the extended release component further comprises one or more release controlling polymers as described herein.
  • the release controlling polymer is hydroxypropyl methyl cellulose (hypromellose), and in particular hydroxypropyl methyl cellulose having a viscosity greater than 10 mPa-s (10 cps) in 2% water at 20°C.
  • the one or more release controlling polymers in the extended release component may be present in an amount of about 10% to about 40%, preferably about 15% to about 35%, or preferably about 20% to about 35%, by weight based on the total weight of the composition.
  • one or more release controlling polymers may be present in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, or about 35%, by weight based on the total weight of the composition.
  • the core further comprises an enteric coating over the extended release component.
  • Any suitable material may be used for the enteric coating. Examples of suitable materials include methacrylic acid-ethyl acrylate copolymer (e.g. Kollicoat MAE), polypropylene glycol and combinations thereof.
  • the enteric coating may further comprise talc.
  • the enteric coating may be present in amount of about 5% to about 25%, and preferably about 10% to about 20%, by weight based on the total weight of the core. In an embodiment, the coating may be present in an amount of about 10%, about 11 %, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19% or about 20%, by weight based on the total weight of the composition.
  • the outer layer may further comprise one or more coating polymers or film formers.
  • the one or more coating polymers or film formers in the outer layer may be present in an amount of about 3% to about 15%, preferably about 4% to about 12%, or preferably about 4% to about 10%, by weight based on the total weight of the composition.
  • one or more coating polymers or film formers may be present in an amount of about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the composition.
  • the one or more coating polymers or film formers in the outer layer may preferably be hydroxypropyl methyl cellulose (hypromellose) having a viscosity less than 10 mPa-s (10 cps) in 2% water at 20°C (e.g., hypromellose E5) or Opadry TF.
  • hydroxypropyl methyl cellulose (hypromellose) having a viscosity less than 10 mPa-s (10 cps) in 2% water at 20°C (e.g., hypromellose E5) or Opadry TF.
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the outer layer may be between about 1 :1 and about 1 :1.4, preferably between about 1 :1 and about 1 :1.3, preferably between about 1 :1 and about 1 :1.2 and preferably about 1 :1.
  • the outer layer consists of an immediate release component consisting of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • the modified release composition may contain one or more pharmaceutically acceptable carriers or excipients as described herein.
  • Pharmaceutically acceptable carriers or excipients may include fillers, diluents, binders, lubricants, glidants, disintegrants, coating polymers or film formers and plasticizers.
  • the extended release component preferably comprises lactose as a filler, more preferably lactose monohydrate.
  • the one or more fillers may be present in an amount of about 20% to about 50%, preferably about 25% to about 45%, and preferably about 30% to about 40%, by weight based on the total weight of the composition. In an embodiment, the one or more fillers may be present in an amount of about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40%, by weight based on the total weight of the composition.
  • the extended release component preferably comprises colloidal anhydrous silica and/or magnesium stearate as the lubricant/glidant, and more preferably a combination of colloidal anhydrous silica and magnesium stearate.
  • the lubricant/glidant may be present in an amount of about 0.1% to about 5%, preferably about 0.5% to about 5%, and preferably about 1 % to about 3%, by weight based on the total weight of the composition.
  • the modified release composition may be free from floating agents and/or gas-generating agents as described herein.
  • the modified release composition according to the present invention may be formulated as a single dosage form, preferably as a single tablet, and more preferably as a single oral tablet.
  • the modified release composition according to the present invention may be manufactured by a granulation process.
  • a modified release composition comprising:
  • a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 7% to about 25% by weight based on the total weight of the composition; one or more release controlling polymers in an amount of about 20% to about 35% by weight based on the total weight of the composition; one or more fillers in an amount of about 25% to about 45% by weight based on the total weight of the composition; and one or more lubricants or glidants in an amount of about 0.5% to about 5% by weight based on the total weight of the composition,
  • an outer layer over said core wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof in an amount of about 2% to about 15% by weight based on the total weight of the composition.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers, and wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more coating polymers or film formers in the immediate release component is between about 1 :1 and about 1 :1.4.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component consisting of dydrogesterone or a pharmaceutically acceptable salt thereof and one or more coating polymers or film formers.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein 20-40% of dydrogesterone may be released over a period of about 0.25 to about 1 hour, 35-55% of dydrogesterone may be released over about 1 to about 3 hours and 45-100% of dydrogesterone may be released over about 3 to about 5 hours.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, wherein said composition releases greater than 30% of dydrogesterone in 1 hour and not less than 90% of dydrogesterone within 5 hours.
  • a modified release composition comprising (a) a core comprising (i) an extended release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof and one or more release controlling polymers, and (ii) an enteric coating over the extended release component and (b) an outer layer over said core, wherein said outer layer comprises an immediate release component comprising dydrogesterone or a pharmaceutically acceptable salt thereof, for use as part of in vitro fertilisation (I VF) treatment.
  • I VF in vitro fertilisation
  • a dosage form comprising a modified release composition as described herein.
  • the dosage form may comprise: (a) a core comprising dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, and b) a coating over said core, wherein said coating comprises one or more film forming polymers.
  • Any suitable film forming polymer may be used for the coating. Examples of suitable film forming polymers include cellulose acetate, ethyl cellulose, hydroxypropyl methylcellulose, polyacrylic resin and combinations thereof.
  • the coating may be present in amount of about 1 % to about 10%, preferably about 2% to about 8%, and preferably about 2% to about 5%, by weight based on the total weight of the core. In an embodiment, the coating may be present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the core. Unless specifically stated otherwise, where the dosage form is coated, it is to be understood that a reference to % weight of the various components of the modified release composition refers to the amount excluding the coating.
  • the total weight of the dosage form may be from about 100 mg to about 350 mg, preferably from about 100 mg to about 300 mg, preferably from about 100 mg to about 250 mg, preferably from about 100 mg to about 200 mg, preferably from about 100 mg to about 150 mg.
  • the dosage form may be formulated as a single unit dosage form.
  • the modified release composition may also be formulated for administration once daily.
  • the modified release composition according to the present invention may be formulated for oral administration.
  • the composition may be formulated as a tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, microtablets in a capsule, minitablets in a capsule, granules in a capsule, pellets, pellets in a capsule, powder, granules, extrudes, pellets, beads or spheroids, suspension or any other suitable dosage form meant for oral administration to a patient.
  • Medical Treatment any other suitable dosage form meant for oral administration to a patient.
  • composition according to the present invention as described herein may be used to treat various indications including gynaecological disorders, infertility, prevention of miscarriages and as a component of menopausal hormone therapy.
  • the modified release composition may be used in the treatment of infertility and/or prevention of miscarriages.
  • the composition may specifically be used in the treatment of infertility due to luteal insufficiency, threatened miscarriage, habitual or recurrent miscarriage during pregnancy, menstrual disorders, dysfunctional bleeding, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, as part of in vitro fertilisation (IVF) treatment and/or as a component of menopausal hormone therapy.
  • the modified release composition may be used in the treatment of endometriosis or as part of in vitro fertilisation (IVF) treatment.
  • provided herein is a method of treating infertility and/or preventing miscarriages in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a modified release composition as described herein.
  • a method of treating endometriosis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a modified release composition as described herein.
  • IVF in vitro fertilisation
  • the present invention also relates to the use of a modified release composition as described herein, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of infertility and/or preventing miscarriages.
  • treating and “treatment” and like terms refer to the administration of dydrogesterone or a pharmaceutically acceptable salt thereof in an amount effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or condition, i.e., indication, and/or to prolong the survival of the patient being treated.
  • dydrogesterone or a pharmaceutically acceptable salt thereof may be used in combination (for example, in a composition as described herein) with one or more pharmaceutically active compounds.
  • the term “therapeutically effective” or “effective amount” indicates that dydrogesterone or a pharmaceutically acceptable salt thereof when administered is sufficient or effective to prevent, alleviate, or ameliorate one or more symptoms of a disease, disorder or medical condition being treated, and/or to prolong the survival of the subject being treated.
  • the therapeutically effective amount will vary depending on the compound, the disease, disorder or condition and its severity and the age, weight, etc., of the patient to be treated.
  • the modified release composition may be administered as a single dosage form.
  • the modified release composition may also be administered once daily.
  • the modified release composition according to the present invention may be administered by oral administration.
  • a modified release composition comprising the steps of:
  • the method of manufacturing the modified release composition may comprise one or more of the following steps: (1) Dry Mixing, (2) Granulation, (3) Drying, (4) Dry Sizing, (5) Blending, (6) Lubrication, (7) Compression and (8) Coating.
  • a dry mixing step may be performed to produce a homogenous powder mixture of drug substance and excipients.
  • dydrogesterone, one or more release controlling polymers (e.g. hypromellose) and a filler (e.g. lactose) may be placed into a rapid mixer granulator, and mixed for a duration of 5 minutes ( ⁇ 5 seconds) at 124 rpm (121 - 127 rpm).
  • Granulation may be performed in a high-shear granulator. More specifically, when dry mixing is completed, granulation may be carried out by addition of water to the dry powder mixture, at a rate between 0.689 to 1.172 kg/minute (target: 1.03 kg/minute) using a peristaltic pump with spray gun 8.0 mm nozzle by keeping impeller at 124 ⁇ 3 rpm (121 - 127 rpm) and chopper at 950 rpm (947 - 953 rpm). Granulation may be continued until the addition of water has been completed, and wet granules are obtained.
  • a drying process of the wet granules may be carried out at a temperature of about 55°C (target 45°C ⁇ 5°C). The drying process may be continued until the loss on drying (LOD) of the granules is between 2.2 - 3.6 % w/w (target: 3.0 % w/w).
  • LOD loss on drying
  • a sizing step may be performed to produce a granulate with the desired flow and compaction properties for downstream processing. More specifically, the granules obtained from the drying step may be sifted through a mesh (1.25 mm) by using a vibratory sifter, and milled using a multimill through 2.50 mm or 1.50 mm screen with impact forward direction at 2500 ⁇ 150 rpm.
  • the blending and lubrication may take place in a bin blender (filling level max. 2/3).
  • the milled granules from the dry sizing step may first be blended with an excipient (e.g. silica, colloidal anhydrous) at about 12 rpm for about 4 min. Afterwards one or more additional glidants/lubricants (e.g. magnesium stearate) may be added and the mixture may be blended at about 12 rpm for about 2 to 3 mins.
  • an excipient e.g. silica, colloidal anhydrous
  • additional glidants/lubricants e.g. magnesium stearate
  • the lubricated tablet blend may be compressed into about 20 or 30 mg tablets according to the following process parameters:
  • a film-coating suspension may be prepared by mixing purified water and coating powder in a liquid manufacturing tank.
  • the tablet core may be coated with the suspension in a perforated pan coater (O’Hara Labcoat M) having about 12.0 inch pan and about 1.2 mm nozzle.
  • Atomizing air pressure 0.7 - 1.0 bar I NLT 0.7 bar
  • the tablets may be dried intermittently during spraying.
  • the coating process may be controlled for weight gain, 2 - 5 % of tablet core weight (target about 3 %).
  • Embodiment 1 a modified release composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, one or more release controlling polymers and one or more pharmaceutically acceptable excipients, wherein said composition releases greater than 20% of dydrogesterone in 1 hour and not less than 80% of dydrogesterone within 5 hours.
  • Embodiment 2 the composition according to Embodiment 1 , wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 10% to about 40%, preferably about 15% to about 40%, preferably about 15% to about 35%, preferably about 16% to about 35%, preferably about 17% to about 34%, preferably about 18% to about 33%, and preferably about 18% to about 32%, by weight based on the total weight of the composition.
  • Embodiment 3 the composition according to Embodiment 2, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21 %, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition.
  • Embodiment 4 the composition according to any one of Embodiments 1 to 3, wherein the dydrogesterone is in a free form.
  • Embodiment 5 the composition according to any one of Embodiments 1 to 4, wherein the composition comprises about 10 mg or more, preferably greater than 10 mg, preferably about 15 to about 40 mg, preferably about 20 to about 40 mg, and preferably about 20 to about 30 mg, and preferably about 20 mg or about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 6 the composition according to Embodiment 5, wherein the composition comprises about 10 mg, about 15 mg, about 20 mg, about 30 mg or about 40 mg, of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 7 the composition according to any one of Embodiments 1 to 6, wherein the one or more release controlling polymers is selected from the group consisting of hydrophilic or hydrophobic polymers comprising one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, xanthan gum, gellan gum, shellac, rosin, zein (prolamine from corn), povidone, kollidon SR (polyvinyl acetate and povidone), a poly(meth)acrylate, poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium al
  • Embodiment 8 the composition according to Embodiment 7, wherein the one or more release controlling polymers is hydroxypropyl methyl cellulose (hypromellose).
  • Embodiment 9 the composition according to any one of Embodiments 1 to 8, wherein the composition contains more than one type of release controlling polymer.
  • Embodiment 10 the composition according to any one of Embodiments 1 to 9, wherein the composition contains two different types of release controlling polymers.
  • Embodiment 11 the composition according to Embodiment 10, wherein the composition contains two different types of hydroxypropyl methyl cellulose (hypromellose) polymers, for example, a combination of methocel K15M and methocel E15LV.
  • hydroxypropyl methyl cellulose hyperromellose
  • Embodiment 12 the composition according to any one of Embodiments 1 to 11 , wherein the one or more release controlling polymers is present in an amount of about 20% to about 60%, preferably about 25% to about 60%, preferably about 25% to about 55%, preferably about 28% to about 50%, preferably about 30% to about 40%, preferably about 30% to about 35%, or preferably about 25% to about 35%, by weight based on the total weight of the composition.
  • Embodiment 13 the composition according to Embodiment 12, wherein the one or more release controlling polymers is present in an amount of about 20%, about 21 %, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41 %, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51 %, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% by weight based on the total weight of the composition.
  • Embodiment 14 the composition according to any one of Embodiments 1 to 13, wherein the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) value relative to that of an immediate release formulation comprising dydrogesterone, of at least about 1.0, or at least about 1.05, or at least about 1.1 , or at least about 1.2, or at least about 1.3, or at least about 1 .4, or at least about 1.5, or at least about 2.0, or at least about 2.5, or at least about 3.0, where the AUC(o-24h) values may be determined under similar conditions, preferably wherein the immediate release formulation comprising dydrogesterone is a commercially available Duphaston® tablet.
  • the immediate release formulation comprising dydrogesterone is a commercially available Duphaston® tablet.
  • Embodiment 15 the composition according to any one of Embodiments 1 to 13, wherein the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to at least two immediate release formulations each comprising 10 mg of dydrogesterone, preferably whrerein the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to 2 to 4, for example 2, 3 or 4 immediate release formulations each comprising 10 mg of dydrogesterone.
  • the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to at least two immediate release formulations each comprising 10 mg of dydrogesterone, preferably whrerein the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to 2 to 4, for example 2, 3 or 4 immediate release formulations each comprising 10 mg of dydrogesterone.
  • Embodiment 16 the composition according to Embodiment 15, wherein the modified release composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to 2 or 3 immediate release formulations each comprising 10 mg of dydrogesterone.
  • Embodiment 17 the composition according to any one of Embodiments 14 to 16, wherein the immediate release formulation comprising 10 mg of dydrogesterone refers to an immediate release product containing 10 mg of dydrogesterone, such as duphaston®.
  • Embodiment 18 the composition according to any one of Embodiments 14 to 17, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to two immediate release formulations each comprising 10 mg of dydrogesterone, such as duphaston®.
  • Embodiment 19 the composition according to any one of Embodiments 14 to 17, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) equivalent to three immediate release formulations each comprising 10 mg of dydrogesterone, such as duphaston®.
  • Embodiment 20 the composition according to any one of Embodiments 1 to 19, wherein the one or more pharmaceutically acceptable excipients is selected from the group consisting of fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • Embodiment 21 the composition according to Embodiment 20, wherein the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, and combinations thereof.
  • the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol,
  • Embodiment 22 the composition according to Embodiment 21 , wherein the filler is lactose, preferably lactose monohydrate.
  • Embodiment 23 the composition according to any one of Embodiments 20 to 22, wherein the filler is present in an amount of about 20% to about 65%, preferably about 20% to about 60%, preferably about 25% to about 60%, preferably about 30% to about 60%, preferably about 30% to about 55%, and preferably about 30% to about 50%, by weight based on the total weight of the composition.
  • Embodiment 24 the composition according to Embodiment 23, wherein the filler is present in an amount of about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41 %, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59% or about 60%, by weight based on the total weight of the composition.
  • Embodiment 25 the composition according to Embodiment 20 wherein the binder is selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K30 or PVP 90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropyl cellulose, copovidone, and combinations thereof.
  • PVP polyvinylpyrrolidone
  • PEG polyethylene glycols
  • hydroxypropyl cellulose hydroxypropyl cellulose
  • copovidone and combinations thereof.
  • Embodiment 26 the composition according to Embodiment 20 or 25, wherein the binder is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 27 the composition according to Embodiment 20 wherein the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • colloidal silicon dioxide e.g., Aerosil 200
  • Embodiment 28 the composition according to Embodiment 27 wherein the lubricant or glidant is colloidal anhydrous silica and/or magnesium stearate.
  • Embodiment 29 the composition according to Embodiment 28 wherein the lubricant or glidant is a combination of colloidal anhydrous silica and magnesium stearate.
  • Embodiment 30 the composition according to any one of Embodiments 20 or 27 to 29, wherein the lubricant or glidant is present in an amount of about 0.1% to about 10%, preferably about 0.5% to about 5%, and preferably about 1% to about 3%, by weight based on the total weight of the composition.
  • Embodiment 31 the composition according to Embodiment 20, wherein the disintegrant is selected from the group consisting of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL), croscarmellose sodium, sodium starch glycolate, polacrillin potassium, low substituted hydroxypropyl cellulose, alginic acid, sodium alginate and guar gum, most preferably crosslinked PVP (crospovidone), crosslinked CMC (Ac-Di-Sol), carboxymethyl starch-Na (pirimojel and explotab) and/or combinations thereof.
  • the disintegrant is selected from the group consisting of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL), cros
  • Embodiment 32 the composition according to Embodiment 20 or 31 , wherein the disintegrant is present in an amount of about 0.01 % to about 15%, preferably about 0.05% to about 12%, and preferably about 0.1% to about 10%, by weight based on the total weight of the composition.
  • Embodiment 33 the composition according to Embodiment 20, wherein the plasticizer is selected from the group consisting of propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • the plasticizer is selected from the group consisting of propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • Embodiment 34 the composition according to Embodiment 20 or 33, wherein the plasticizer is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 35 the composition according to any one of Embodiments 1 to 34, wherein the composition is free from floating agents.
  • Embodiment 36 the composition according to Embodiment 35, wherein the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • Embodiment 37 the composition according to any one of Embodiments 1 to 36, wherein the composition is free from gas-generating agents.
  • Embodiment 38 the composition according to Embodiment 37, wherein the gas-generating agent is selected from the group consisting of carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • the gas-generating agent is selected from the group consisting of carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • Embodiment 39 the composition according to any one of Embodiments 1 to 38, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers is between about 1 :6 and about 2:1 , preferably between about 1 :4 and about 3:2, preferably between about 1 :2 and about 4:3 and preferably between about 1 :2 and about 1 :1.
  • Embodiment 40 the composition according to any one of Embodiments 20 to 24 or 35 to 39, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler is between about 1 :6 and about 2:1 , preferably between about 1 :4 and about 3:2, preferably between about 1 :3 and about 2:1 , and preferably between about 1 :3 and about 1 :1.
  • Embodiment 41 the composition according to any one of Embodiments 20 to 24 or 35 to 40, wherein the weight ratio between the filler and the one or more release controlling polymers is between about 1 :3 and about 5:2, preferably between about 1 :2 and about 7:3, preferably between about 3:4 and about 2:1 , and preferably between about 4:5 and about 5:3.
  • Embodiment 42 the composition according to any one of Embodiments 1 to 41 , wherein the composition is manufactured by a granulation process.
  • Embodiment 43 a modified release composition comprising 15 to 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein said composition provides a mean dydrogesterone plasma AUC(o-24h) of 10 to 25 ng*hr/mL.
  • Embodiment 44 the composition according to Embodiment 43, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 15% to about 25%, preferably about 16% to about 24%, preferably about 17% to about 23%, preferably about 18% to about 22%, preferably about 19% to about 21 %, and preferably about 20%, by weight based on the total weight of the composition.
  • Embodiment 45 the composition according to Embodiment 44, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24% or about 25%, by weight based on the total weight of the composition.
  • Embodiment 46 the composition according to any one of Embodiments 43 to 45, wherein the dydrogesterone is in a free form.
  • Embodiment 47 the composition according to any one of Embodiments 43 to 46, wherein the composition comprises about 15 to about 25 mg, preferably about 16 to about 24 mg, preferably about 17 to about 23 mg, preferably about 18 to about 22 mg, preferably about 19 to about 21 mg and preferably about 20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 48 the composition according to Embodiment 47, wherein the composition comprises about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg or about 25 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 49 the composition according to Embodiment 48, wherein the composition comprises 20 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 51 the composition according to Embodiment 50, wherein the one or more release controlling polymers is hydroxypropyl methyl cellulose (hypromellose).
  • Embodiment 52 the composition according to any one of Embodiments 43 to 51 , wherein the composition contains more than one type of release controlling polymer.
  • Embodiment 53 the composition according to any one of Embodiments 43 to 52, wherein the composition contains two different types of release controlling polymers.
  • Embodiment 54 the composition according to Embodiment 53, wherein the composition contains two different types of hydroxypropyl methyl cellulose (hypromellose) polymers, for example, a combination of methocel K15M and methocel E15LV.
  • hydroxypropyl methyl cellulose hyperromellose
  • Embodiment 55 the composition according to any one of Embodiments 43 to 54, wherein the one or more release controlling polymers is present in an amount of about 30% to about 40%, preferably about 31% to about 39%, preferably about 32% to about 38%, preferably about 33% to about 37%, and preferably about 34 to about 36% by weight based on the total weight of the composition.
  • Embodiment 56 the composition according to Embodiment 55, wherein the one or more release controlling polymers is present in an amount of about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition.
  • Embodiment 57 the composition according to any one of Embodiments 43 to 56, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) of about 10 to about 25 ng*hr/mL, preferably about 10 to about 20 ng*hr/mL, preferably about 15 to about 20 ng*hr/mL and preferably about 15 to about 19 ng*hr/mL.
  • Embodiment 58 the composition according to Embodiment 57, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) of about 10 ng*hr/mL, preferably about 11 ng*hr/mL, preferably about 12 ng*hr/mL, preferably about 13 ng*hr/mL, preferably about 14 ng*hr/mL, preferably about 15 ng*hr/mL, preferably about 16 ng*hr/mL, preferably about 17 ng*hr/mL, preferably about 18 ng*hr/mL, preferably about 19 ng*hr/mL, preferably about 20 ng*hr/mL, preferably about 21 ng*hr/mL, preferably about 22 ng*hr/mL, preferably about 23 ng*hr/mL, preferably about 24 ng*hr/mL or preferably 25 ng*hr/mL.
  • Embodiment 59 the composition according to any one of Embodiments 43 to 58, wherein the composition provides a mean dydrogesterone plasma C ma x of about 2 to about 5 ng/mL, preferably about 2 to about 4 ng/mL, preferably about 2 to about 3 ng/mL, and preferably about 2.5 to about 3 ng/mL.
  • Embodiment 60 the composition according to Embodiment 59, wherein the composition provides a mean dydrogesterone plasma C ma x of about 2 ng/mL, preferably about 2.1 ng/mL, preferably about 2.2 ng/mL, preferably about 2.3 ng/mL, preferably about 2.4 ng/mL, preferably about 2.5 ng/mL, preferably about 2.6 ng/mL, preferably about 2.7 ng/mL, preferably about 2.8 ng/mL, preferably about 2.9 ng/mL, preferably about 3.0 ng/mL, preferably about 3.1 ng/mL, preferably about 3.2 ng/mL, preferably about 3.3 ng/mL, preferably about 3.4 ng/mL, preferably about 3.5 ng/mL, preferably about 3.6 ng/mL, preferably about 3.7 ng/mL, preferably about 3.8 ng/mL, preferably about 3.9 ng/mL,
  • Embodiment 61 the composition according to any one of Embodiments 43 to 60, wherein the composition provides a mean dihydrodydrogesterone plasma AUC(o-24h) of about 350 to about 750 ng*hr/mL, preferably about 400 to about 700 ng*hr/mL, preferably about 450 to about 650 ng*hr/mL, preferably about 500 to about 600 ng*hr/mL, and preferably about 500 to about 550 ng*hr/mL.
  • AUC(o-24h) of about 350 to about 750 ng*hr/mL, preferably about 400 to about 700 ng*hr/mL, preferably about 450 to about 650 ng*hr/mL, preferably about 500 to about 600 ng*hr/mL, and preferably about 500 to about 550 ng*hr/mL.
  • Embodiment 62 the composition according to Embodiment 61 , wherein the composition provides a mean dihydrodydrogesterone plasma AUC(o-24h) of about 350 ng*hr/mL, preferably about 360 ng*hr/mL, preferably about 370 ng*hr/mL, preferably about 380 ng*hr/mL, preferably about 390 ng*hr/mL, preferably about 400 ng*hr/mL, preferably about 410 ng*hr/mL, preferably about 420 ng*hr/mL, preferably about 430 ng*hr/mL, preferably about 440 ng*hr/mL, preferably about 450 ng*hr/mL, preferably about 460 ng*hr/mL, preferably about 470 ng*hr/mL, preferably about 480 ng*hr/mL, preferably about 490 ng*hr/mL, preferably about 500 ng
  • Embodiment 63 the composition according to any one of Embodiments 43 to 62, wherein the composition provides a mean dihydrodydrogesterone plasma C ma x of about 50 to about 110 ng/mL, preferably about 55 to about 105 ng/mL, preferably about 60 to about 100 ng/mL, preferably about 65 to about 95 ng/mL, preferably about 70 to about 90 ng/mL, and preferably about 75 to about 85 ng/mL.
  • Embodiment 64 the composition according to Embodiment 63, wherein the composition provides a mean dihydrodydrogesterone plasma C ma x of about 50 ng/mL, preferably about 51 ng/mL, preferably about 52 ng/mL, preferably about 53 ng/mL, preferably about 54 ng/mL, preferably about 55 ng/mL, preferably about 56 ng/mL, preferably about 57 ng/mL, preferably about 58 ng/mL, preferably about 59 ng/mL, preferably about 60 ng/mL, preferably about 61 ng/mL, preferably about 62 ng/mL, preferably about 63 ng/mL, preferably about 64 ng/mL, preferably about 65 ng/mL, preferably about 66 ng/mL, preferably about 67 ng/mL, preferably about 68 ng/mL, preferably about 69 ng/mL, preferably about 70 ng/m
  • Embodiment 65 the composition according to any one of Embodiments 43 to 64, wherein the AUC(o-24h) and/or C ma x values are measured when a patient is in a fasted state.
  • Embodiment 66 the composition according to Embodiment 65, wherein the fasted state refers to a state where the patient is provided with no food for at least 10 hours prior to dosing.
  • Embodiment 67 the composition according to any one of Embodiments 43 to 66, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients.
  • Embodiment 68 the composition according to Embodiment 69, wherein the one or more pharmaceutically acceptable carriers or excipients is selected from the group consisting of fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • the one or more pharmaceutically acceptable carriers or excipients is selected from the group consisting of fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • Embodiment 69 the composition according to Embodiment 68, wherein the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, and combinations thereof.
  • the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylito
  • Embodiment 70 the composition according to Embodiment 69, wherein the filler is lactose, preferably lactose monohydrate.
  • Embodiment 71 the composition according to any one of Embodiments 68 to 70, wherein the filler is present in an amount of about 35% to about 55%, preferably about 40% to about 50%, preferably about 41% to about 49%, preferably about 42% to about 48%, and preferably about 43% to about 47%, by weight based on the total weight of the composition.
  • Embodiment 72 the composition according to Embodiment 71 , wherein the filler is present in an amount of about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41 %, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51 %, about 52%, about 53%, about 54%, or about 55%, by weight based on the total weight of the composition.
  • Embodiment 73 the composition according to Embodiment 68 wherein the binder is selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K30 or PVP 90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropyl cellulose, copovidone, and combinations thereof.
  • Embodiment 74 the composition according to Embodiment 68 or 73, wherein the binder is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 75 the composition according to Embodiment 68 wherein the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • colloidal silicon dioxide e.g., Aerosil
  • Embodiment 76 the composition according to Embodiment 75 wherein the lubricant or glidant is colloidal anhydrous silica and/or magnesium stearate.
  • Embodiment 77 the composition according to Embodiment 76 wherein the lubricant or glidant is a combination of colloidal anhydrous silica and magnesium stearate.
  • Embodiment 78 the composition according to any one of Embodiments 68 or 75 to 77, wherein the lubricant or glidant is present in an amount of about 0.1% to about 10%, preferably about 0.5% to about 5%, and preferably about 1% to about 3%, by weight based on the total weight of the composition.
  • Embodiment 79 the composition according to Embodiment 68, wherein the disintegrant is selected from the group consisting of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL), croscarmellose sodium, sodium starch glycolate, polacrillin potassium, low substituted hydroxypropyl cellulose, alginic acid, sodium alginate and guar gum, most preferably crosslinked PVP (crospovidone), crosslinked CMC (Ac-Di-Sol), carboxymethyl starch-Na (pirimojel and explotab) and/or combinations thereof.
  • the disintegrant is selected from the group consisting of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL),
  • Embodiment 80 the composition according to Embodiment 68 or 79, wherein the disintegrant is present in an amount of about 0.01 % to about 15%, preferably about 0.05% to about 12%, and preferably about 0.1% to about 10%, by weight based on the total weight of the composition.
  • Embodiment 81 the composition according to Embodiment 68, wherein the plasticizer is selected from the group consisting of propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • Embodiment 82 the composition according to Embodiment 68 or 81 , wherein the plasticizer is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 83 the composition according to any one of Embodiments 43 to 82, wherein the composition is free from floating agents.
  • Embodiment 84 the composition according to Embodiment 83, wherein the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • Embodiment 85 the composition according to any one of Embodiments 43 to 84, wherein the composition is free from gas-generating agents.
  • Embodiment 86 the composition according to Embodiment 85, wherein the gas-generating agent is selected from the group consisting of carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • the gas-generating agent is selected from the group consisting of carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • Embodiment 87 the composition according to any one of Embodiments 43 to 86, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers is between about 2:5 and about 5:6, preferably between about 2:3 and about 4:5 and preferably between about 1 :2 and about 2:3.
  • Embodiment 88 the composition according to any one of Embodiments 68 to 70 or 83 to 87, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler is between about 1 :3 and about 4:5, preferably between about 1 :3 and about 3:5, and preferably between about 2:5 and about 1 :1.
  • Embodiment 89 the composition according to any one of Embodiments 68 to 70 or 83 to 88, wherein the weight ratio between the filler and the one or more release controlling polymers is between about 9:10 and about 2:1 , preferably between about 1 :1 and about 3:2, and preferably between about 5:4 and about 4:3.
  • Embodiment 90 the composition according to any one of Embodiments 43 to 89, wherein the composition is manufactured by a granulation process.
  • Embodiment 91 the composition according to any one of Embodiments 43 to 90, wherein 15- 70% of dydrogesterone is released over a period of about 0.5 to about 2 hours, 35-90% of dydrogesterone is released over about 1 to about 3 hours and 80-100% of dydrogesterone is released over about 2.5 to about 4 hours.
  • Embodiment 92 a modified release composition comprising 26 to 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof; and one or more release controlling polymers, wherein said composition provides a mean dydrogesterone plasma AUC(o-24h) of 10 to 70 ng*hr/mL.
  • Embodiment 93 the composition according to Embodiment 92, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 10% to about 35%, preferably about 15% to about 35%, preferably about 20% to about 35%, preferably about 25% to about 35%, preferably about 28% to about 32%, and preferably about 30%, by weight based on the total weight of the composition.
  • Embodiment 94 the composition according to Embodiment 93, wherein the dydrogesterone or a pharmaceutically acceptable salt thereof is present in an amount of about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, or about 35%, by weight based on the total weight of the composition.
  • Embodiment 95 the composition according to any one of Embodiments 92 to 94, wherein the dydrogesterone is in a free form.
  • Embodiment 96 the composition according to any one of Embodiments 92 to 95, wherein the composition comprises about 26 to about 35 mg, preferably about 27 to about 34 mg, preferably about 28 to about 33 mg, preferably about 29 to about 32 mg, and preferably about 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 97 the composition according to Embodiment 96, wherein the composition comprises about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg or about 35 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 98 the composition according to Embodiment 97, wherein the composition comprises 30 mg of dydrogesterone or a pharmaceutically acceptable salt thereof.
  • Embodiment 99 the composition according to any one of Embodiments 92 to 98, wherein the one or more release controlling polymers is selected from the group consisting of hydrophilic or hydrophobic polymers comprising one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, xanthan gum, gellan gum, shellac, rosin, zein (prolamine from corn), povidone, kollidon SR (polyvinyl acetate and povidone), a poly(meth)acrylate, poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid
  • Embodiment 100 the composition according to Embodiment 99, wherein the one or more release controlling polymers is hydroxypropyl methyl cellulose (hypromellose).
  • Embodiment 101 the composition according to any one of Embodiments 92 to 100, wherein the composition contains more than one type of release controlling polymer.
  • Embodiment 102 the composition according to any one of Embodiments 92 to 101 , wherein the composition contains two different types of release controlling polymers.
  • Embodiment 103 the composition according to Embodiment 102, wherein the composition contains two different types of hydroxypropyl methyl cellulose (hypromellose) polymers, for example, a combination of methocel K15M and methocel E15LV.
  • hydroxypropyl methyl cellulose hyperromellose
  • Embodiment 104 the composition according to any one of Embodiments 92 to 103, wherein the one or more release controlling polymers is present in an amount of about 25% to about 40%, preferably about 26% to about 39%, preferably about 27% to about 38%, preferably about 28% to about 37%, and preferably about 29% to about 36% by weight based on the total weight of the composition.
  • Embodiment 105 the composition according to Embodiment 104, wherein the one or more release controlling polymers is present in an amount of about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31 %, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39% or about 40%, by weight based on the total weight of the composition.
  • Embodiment 106 the composition according to any one of Embodiments 92 to 105, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) of about 10 to about 70 ng*hr/mL, preferably about 15 to about 65 ng*hr/mL, preferably about 20 to about 60 ng*hr/mL, preferably about 25 to about 55 ng*hr/mL, preferably about 30 to about 50 ng*hr/mL, and preferably about 35 to about 45 ng*hr/mL.
  • AUC(o-24h) of about 10 to about 70 ng*hr/mL, preferably about 15 to about 65 ng*hr/mL, preferably about 20 to about 60 ng*hr/mL, preferably about 25 to about 55 ng*hr/mL, preferably about 30 to about 50 ng*hr/mL, and preferably about 35 to about 45 ng*hr/mL.
  • Embodiment 107 the composition according to Embodiment 106, wherein the composition provides a mean dydrogesterone plasma AUC(o-24h) of about 10 ng*hr/mL, preferably about 11 ng*hr/mL, preferably about 12 ng*hr/mL, preferably about 13 ng*hr/mL, preferably about 14 ng*hr/mL, preferably about 15 ng*hr/mL, preferably about 16 ng*hr/mL, preferably about 17 ng*hr/mL, preferably about 18 ng*hr/mL, preferably about 19 ng*hr/mL, preferably about 20 ng*hr/mL, preferably about 21 ng*hr/mL, preferably about 22 ng*hr/mL, preferably about 23 ng*hi7mL, preferably about 24 ng*hr/mL, preferably about 25 ng*hr/mL, preferably about 26 ng
  • Embodiment 108 the composition according to any one of Embodiments 92 to 107, wherein the composition provides a mean dydrogesterone plasma C ma x of about 1.5 to about 7.5 ng/mL, preferably about 2 to about 7 ng/mL, preferably about 3 to about 6 ng/mL and preferably about 4 to about 5 ng/mL.
  • Embodiment 109 the composition according to Embodiment 108, wherein the composition provides a mean dydrogesterone plasma C ma x of about 1.5 ng/mL, preferably about 1.6 ng/mL, preferably about 1.7 ng/mL, preferably about 1.8 ng/mL, preferably about 1.9 ng/mL, preferably about 2.0 ng/mL, preferably about 2.1 ng/mL, preferably about 2.2 ng/mL, preferably about 2.3 ng/mL, preferably about 2.4 ng/mL, preferably about 2.5 ng/mL, preferably about 2.6 ng/mL, preferably about 2.7 ng/mL, preferably about 2.8 ng/mL, preferably about 2.9 ng/mL, preferably about 3.0 ng/mL, preferably about 3.1 ng/mL, preferably about 3.2 ng/mL, preferably about 3.3 ng/mL, preferably about 3.4 ng/mL,
  • Embodiment 110 the composition according to any one of Embodiments 92 to 109, wherein the composition provides a mean dihydrodydrogesterone plasma AUC(o-24h) of about 400 to about 2200 ng*hr/mL, preferably about 500 to about 2000 ng*hr/mL, preferably about 600 to about 1800 ng*hr/mL, and preferably about 700 to about 1500 ng*hr/mL.
  • Embodiment 111 the composition according to Embodiment 110, wherein the composition provides a mean dihydrodydrogesterone plasma AUC(o-24h) of about 400 ng*hr/mL, preferably about 450 ng*hr/mL, preferably about 500 ng*hr/mL, preferably about 550 ng*hr/mL, preferably about 600 ng*hr/mL, preferably about 650 ng*hr/mL, preferably about 700 ng*hr/mL, preferably about 750 ng*hr/mL, preferably about 800 ng*hr/mL, preferably about 850 ng*hr/mL, preferably about 900 ng*hr/mL, preferably about 950 ng*hr/mL, preferably about 1000 ng*hr/mL, preferably about 1050 ng*hr/mL, preferably about 1100 ng*hr/mL, preferably 1150 ng*hr/
  • Embodiment 112 the composition according to any one of Embodiments 92 to 111 , wherein the composition provides a mean dihydrodydrogesterone plasma C ma x of about 40 to about 200 ng/mL, preferably about 50 to about 175 ng/mL, preferably about 60 to about 150 ng/mL, and preferably about 70 to about 120 ng/mL.
  • Embodiment 113 the composition according to Embodiment 112, wherein the composition provides a mean dihydrodydrogesterone plasma C ma x of about 40 ng/mL, preferably about 45 ng/mL, preferably about 50 ng/mL, preferably about 55 ng/mL, preferably about 60 ng/mL, preferably about 65 ng/mL, preferably about 70 ng/mL, preferably about 75 ng/mL, preferably about 80 ng/mL, preferably about 85 ng/mL, about 90 ng/mL, preferably about 95 ng/mL, preferably about 100 ng/mL, preferably about 105 ng/mL, preferably about 110 ng/mL, preferably about 115 ng/mL, preferably about 120 ng/mL, preferably about 125 ng/mL, preferably about 130 ng/mL, preferably about 135 ng/mL, preferably about 140 ng/mL, preferably about 145
  • Embodiment 114 the composition according to any one of Embodiments 92 to 113, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients.
  • Embodiment 115 the composition according to Embodiment 114, wherein the one or more pharmaceutically acceptable carriers or excipients is selected from the group consisting of fillers, diluents, binders, lubricants, glidants, disintegrants and plasticizers.
  • Embodiment 116 the composition according to Embodiment 115, wherein the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, and combinations thereof.
  • the filler or diluent is selected from the group consisting of starch, corn starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose, lactose monohydrate, cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylito
  • Embodiment 117 the composition according to Embodiment 116, wherein the filler is lactose, preferably lactose monohydrate.
  • Embodiment 118 the composition according to any one of Embodiments 115 to 117, wherein the filler is present in an amount of about 30% to about 65%, preferably about 30% to about 60%, preferably about 30% to about 50%, preferably about 30% to about 45%, and preferably about 30% to about 40%, by weight based on the total weight of the composition.
  • Embodiment 119 the composition according to Embodiment 118, wherein the filler is present in an amount of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41 %, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61 %, about 62%, about 63%, about 64%, or about 65%, by weight based on the total weight of the composition.
  • Embodiment 120 the composition according to Embodiment 115 wherein the binder is selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K30 or PVP 90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropyl cellulose, copovidone, and combinations thereof.
  • PVP polyvinylpyrrolidone
  • PEG polyethylene glycols
  • Embodiment 121 the composition according to Embodiment 115 or 118, wherein the binder is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 122 the composition according to Embodiment 115 wherein the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • the lubricant or glidant is selected from the group consisting of zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silicon dioxide (e.g., Aerosil 200), colloidal anhydrous silica, aluminum or calcium silicate, stearic acid, cutina, magnesium trisilicate, powdered cellulose, talc and combinations thereof.
  • colloidal silicon dioxide e.g., Aeros
  • Embodiment 123 the composition according to Embodiment 122 wherein the lubricant or glidant is colloidal anhydrous silica and/or magnesium stearate.
  • Embodiment 124 the composition according to Embodiment 123 wherein the lubricant or glidant is a combination of colloidal anhydrous silica and magnesium stearate.
  • Embodiment 125 the composition according to any one of Embodiments 115 or 122 to 124, wherein the lubricant or glidant is present in an amount of about 0.1 % to about 10%, preferably about 0.5% to about 5%, and preferably about 1% to about 3%, by weight based on the total weight of the composition.
  • Embodiment 126 the composition according to Embodiment 115, wherein the disintegrant is selected from the group consisting of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g.
  • crospovidone polyplasdone XL or kollidon CL
  • croscarmellose sodium sodium starch glycolate
  • polacrillin potassium low substituted hydroxypropyl cellulose
  • alginic acid sodium alginate and guar gum
  • crosslinked PVP crospovidone
  • crosslinked CMC Ac-Di-Sol
  • carboxymethyl starch-Na pirimojel and explotab
  • Embodiment 127 the composition according to Embodiment 115 or 126, wherein the disintegrant is present in an amount of about 0.01 % to about 15%, preferably about 0.05% to about 12%, and preferably about 0.1% to about 10%, by weight based on the total weight of the composition.
  • Embodiment 128 the composition according to Embodiment 115, wherein the plasticizer is selected from the group consisting of propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • the plasticizer is selected from the group consisting of propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate and polyethylene glycol.
  • Embodiment 129 the composition according to Embodiment 115 or 128, wherein the plasticizer is present in an amount of about 0.1 % to about 20%, preferably about 0.5% to about 15%, and preferably about 1 % to about 10%, by weight based on the total weight of the composition.
  • Embodiment 130 the composition according to any one of Embodiments 92 to 129, wherein the composition is free from floating agents.
  • Embodiment 131 the composition according to Embodiment 130, wherein the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • the floating agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
  • Embodiment 132 the composition according to any one of Embodiments 92 to 131 , wherein the composition is free from gas-generating agents.
  • Embodiment 133 the composition according to Embodiment 132, wherein the gas-generating agent is selected from the group consisting of carbonate and bicarbonate salts, that generate CO2 in the presence of acidic gastric fluid such as citric acid.
  • Embodiment 134 the composition according to any one of Embodiments 92 to 133, wherein the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the one or more release controlling polymers is between about 1 :4 and about 3:2, preferably between about 2:5 and about 5:4 and preferably between about 1 :2 and about 6:5.
  • Embodiment 135 the composition according to any one of Embodiments 115 to 119 or 130 to
  • the weight ratio between dydrogesterone or a pharmaceutically acceptable salt thereof and the filler is between about 1 :6 and about 6:5, preferably between about 1 :3 and about 6:5, and preferably between about 1 :2 and about 7:6.
  • Embodiment 136 the composition according to any one of Embodiments 115 to 119 or 130 to
  • Embodiment 137 the composition according to any one of Embodiments 92 to 136, wherein the composition is manufactured by a granulation process.
  • Embodiment 138 the composition according to any one of Embodiments 92 to 137, wherein 20- 30% of dydrogesterone is released over a period of about 0.5 to about 2 hours, 50-90% of dydrogesterone is released over about 1 to about 3 hours and 80-100% of dydrogesterone is released over about 2 to about 4.5 hours.
  • Embodiment 139 A dosage form comprising (a) a core comprising the composition according to any one of Embodiments 1 to 138 and b) a coating over said core, wherein said coating comprises one or more film forming polymers.
  • Embodiment 140 the dosage form according to Embodiment 139, wherein the film forming polymer is selected from the group consisting of cellulose acetate, ethyl cellulose, hydroxypropyl methylcellulose, polyacrylic resin and combinations thereof.
  • Embodiment 141 the dosage form according to Embodiment 139 or 140, wherein the coating is present in amount of about 1 % to about 10%, preferably about 2% to about 8%, and preferably about 2% to about 5%, by weight based on the total weight of the core.
  • Embodiment 142 the dosage form according to Embodiment 141 , wherein the coating is present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, by weight based on the total weight of the core.
  • Embodiment 143 the dosage form according to any one of Embodiments 139 to 142, wherein the total weight of the dosage form is from about 100 mg to about 350 mg, preferably from about 100 mg to about 300 mg, preferably from about 100 mg to about 250 mg, preferably from about 100 mg to about 200 mg, preferably from about 100 mg to about 150 mg.
  • Embodiment 144 the dosage form according to any one of Embodiments 139 to 143, wherein the dosage is be formulated as a single unit dosage form, preferably as a single tablet, and more preferably as a single oral tablet.
  • Embodiment 145 the dosage form according to any one of Embodiments 139 to 144, wherein the dosage is be formulated for administration once daily.
  • Embodiment 146 the dosage form according to any one of Embodiments 139 to 145, wherein the dosage form is formulated for oral administration.
  • Embodiment 147 the dosage form according to Embodiment 146, wherein the dosage form is formulated as a tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, microtablets in a capsule, minitablets in a capsule, granules in a capsule, pellets, pellets in a capsule, powder, granules, extrudes, pellets, beads or spheroids, suspension or any other suitable dosage form meant for oral administration to a patient.
  • a tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, microtablets in a capsule, minitablets in a capsule, granules in a capsule, pellets, pellets in a capsule, powder, granules, extrudes, pellets
  • Embodiment 148 the composition or dosage form according to any one of Embodiments 1 to 147, for use in the treatment of gynaecological disorders, infertility, prevention of miscarriages and as a component of menopausal hormone therapy.
  • Embodiment 149 the composition or dosage form according to Embodiment 148, for use in the treatment of infertility and/or prevention of miscarriages.
  • Embodiment 150 the composition or dosage form according to Embodiment 148 or 149, for use in the treatment of infertility due to luteal insufficiency, threatened miscarriage, habitual or recurrent miscarriage during pregnancy, menstrual disorders, dysfunctional bleeding, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, as part of in vitro fertilisation (IVF) treatment and/or as a component of menopausal hormone therapy.
  • IVF in vitro fertilisation
  • Embodiment 151 the composition or dosage form according to Embodiment 150, for use in the treatment of endometriosis or as part of in vitro fertilisation (IVF) treatment.
  • IVF in vitro fertilisation
  • Embodiment 152 a method of treating infertility and/or preventing miscarriages in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the composition or dosage form according to any one of embodiments 1 to 147.
  • Embodiment 153 the method according to Embodiment 152, wherein the method is for treating endometriosis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the composition or dosage form according to any one of embodiments 1 to 147.
  • Embodiment 154 a method of administering to the patient a therapeutically effective amount of the composition or dosage form according to any one of embodiments 1 to 147, as part of in vitro fertilisation (IVF) treatment.
  • IVF in vitro fertilisation
  • eligible subjects were checked into the clinical pharmacology unit (CPU) and were given dinner. Thereafter, subjects were fasted for at least 10.00 hours prior to dosing.
  • CPU clinical pharmacology unit
  • test product (A) which corresponds to Composition 1 of Example 1 and reference product (B) was as follows:
  • test product (A) For administration of test product (A) and first dose of reference product (B):
  • test product (A) or first dose of reference product (B) were orally administered one tablet of either test product (A) or first dose of reference product (B) with 240 ⁇ 2 mL of drinking water at ambient temperature in an upright sitting position as per the randomization schedule.
  • subjects were orally administered one tablet of second dose of reference product (B) with 240 ⁇ 2 mL of drinking water at ambient temperature in an upright sitting position as per the randomization schedule.
  • IPs investigational products
  • PK parameters were calculated using a non-compartmental analysis model using Phoenix® WinNonlin® - Software, Version 8.3.5 (Certara USA, Inc.) for PK analysis of Dydrogesterone and Dihydrodydrogesterone.
  • ANOVA was performed at 5% level of significance on natural In-transformed PK parameters AUCo-t and AUCo- tau to determine whether the average values for these PK measures determined after administration of the test and reference products are comparable. This involved the calculation of 90% Cl for the ratio of the averages (population geometric least square means) of the measures for test and reference products.
  • the ANOVA model included sequence subject nested within the sequence, period and treatment as fixed effects factors. The significance of the sequence effect was tested using the subject nested within the sequence as the error term. Each ANOVA testing also included calculation of LSM, adjusted differences between formulation means and the standard error associated with these differences.
  • Geometric least square mean values were reported for In-transformed primary PK parameters of Dydrogesterone and Dihydrodydrogesterone on which Cl is based. Ratios of geometric least square means are expressed as a percentage of the LSM for the test and reference products.
  • Test product was considered bioequivalent to reference product, if 90% Cis for ratio (test/reference) of geometric least square means based on In-transformed primary PK parameters - ALICo-t and AUCo-tau fall within acceptable BE limits of 80.00% to 125.00% for Dydrogesterone.
  • value is the least-squares geometric mean.
  • Ratio% of geometric least-squares means for log e -transformed results.
  • ISCV% %lntra-subject coefficient of variation calculated from the mean square term of the ANOVA.
  • value is the least-squares geometric mean.
  • Ratio% of geometric least-squares means for log e -transformed results.
  • ISCV% %lntra-subject coefficient of variation calculated from the mean square term of the ANOVA.
  • Table 8 Dissolution profile for 30 mg dydrogesterone MR tablet (Composition 5)
  • the 20 mg once- daily modified release formulation could be a suitable alternate treatment option to the twice-daily 10 mg immediate release formulation, offering comparable efficacy with a convenient once daily dosing schedule.
  • the safety profile observed in this study under 20 mg once-daily modified release formulation for treatment of endometriosis can be considered similar to the safety profile under twice-daily 10 mg immediate release formulation.
  • composition 8 A dual immediate release I extended release tablet (composition 8) was prepared with the components as set out below: Composition 8
  • a tablet according to composition 8 was prepared according to the following method.
  • Granulation the powder blend was mixed at 500 rpm impeller speed for 5 min. The impeller speed was increased to 750 rpm and the chopper speed was set to 1500 rpm, when the addition of the granulation liquid (2% w/v HPMC E15 solution in water) was started (dropwise addition). A total of 100 g granulation liquid was added in 10 min (10 g/min) and then granulation was continued for another 10 min under the same conditions. The LOD of the wet mass was 24% corresponding well with the added amount of water (24.7% based on total weight).
  • wet sieving the wet mass was passed through a 2000 pm sieve.
  • Tablet coating the extended release component was coated with the immediate release component using a dydrogesterone : HPMC E5 1:1 solution in a side vented pan coater to obtain the targeted 10% weight gain.
  • the immediate release component of the tablet dissolved within the first 15 minutes. Thereafter the extended release component released about 80% of the loading over about 3.5 - 4 hours.
  • the immediate release I extended release combination was feasibly formulated and the formulation of the extended release core tablet and the immediate release component showed appropriate tablet properties.
  • composition 9 A dual immediate release I extended release tablet (composition 9) was prepared with the components as set out below: Composition 9
  • a tablet according to composition 9 was prepared according to the following method.
  • Granulation the powder blend was mixed at 500 rpm impeller speed for 5 min. The impeller speed was increased to 750 rpm and the chopper speed was set to 1500 rpm, when the addition of the granulation liquid (2% w/v HPMC E15 solution in water) was started (dropwise addition). Granulation liquid was added in 8:23 min (10 g/min) and then granulation was continued for another 5 min under the same conditions. The LOD of the wet mass was 21 % corresponding well with the added amount of water (21 .5% based on total weight).
  • wet sieving the wet mass was passed through a 2000 pm sieve. Drying: the drying was performed at 40°C for 16 hours.
  • Tablet enteric coating the tablet cores were coated with an enteric coating layer based on Kollicoat MAE 30 DP.
  • Tablet outer coating the enterically coated extended release component was coated with the immediate release component using a dydrogesterone : HPMC E5 1:1 solution in a side vented pan coater to obtain the targeted weight gain.
  • a dissolution experiment was performed for the tablet according to composition 9 over 6 hours (basket at 150 rpm, 37°C) with UV-detection.
  • the release medium 500 ml
  • the release medium consisted of sodium lauryl sulfate (0.3%) dissolved in 0.1 N HCI during a 2-hour acid stage and it was exchanged with 500 ml of sodium lauryl sulfate (0.3%) dissolved in 50 mM sodium phosphate buffer pH 6.8 thereafter.
  • the results are presented below.
  • Drug release occurred over about 4.5 hours and showed two distinct release phases due to the immediate release component released during the acid stage and the extended release component released within 2.5 hours in the buffer stage.
  • composition 10 A dual immediate release I extended release tablet (composition 10) was prepared with the components as set out below:
  • a tablet according to composition 10 was prepared according to the following method.
  • Dydrogesterone micronised and excipients were each screened through a 1000 pm sieve and loaded into the HS mixer and mixed for 5 min. Granulation liquid was then pumped into the bed at 9-10 g/min per peristaltic pump. The amount of water added as granulation liquid corresponded to 28% w/w of total solids in the powder blend (dydrogesterone micronised, HPMCs and lactose). Granulation was continued for 5 min (total granulation time: 15 min) under the same conditions after which the material was unloaded, wet screened (1000 pm) and dried overnight at 40°C.
  • Tablet compression granules and colloidal silica were each screened through a 1000 pm sieve, loaded (about 70% fill) into a mixer and mixed for 10 minutes at 49 rpm. Magnesium stearate was screened through a 180 pm sieve, added to the granule blend and mixed (lubrication) in a blender for 3 min at 49 rpm.
  • Tablets were compressed with an instrumented single punch tableting machine.
  • Drug-Layered SR tablets tablet cores were layered with drug:HPMC E5 1 :1 (7.14% solids content) using a drum coater with perforated pan.
  • composition 11 A dual immediate release I extended release tablet (composition 11) was prepared with the components as set out below:
  • a tablet according to composition 11 was prepared according to the following method.
  • Hypromellose (Methocel K15) 2208, Hypromellose (Methocel E15LV) 2910 and Lactose monohydrate were sifted through #20 mesh using vibratory sifter and collected separately in a double lined polythene bag in a HDPE container.
  • the FBD bowl was attached to the FBD and the drying process was started with inlet temperature of NMT 55°C (Target 45°C ⁇ 5°C) and suitable air flow.
  • the product temperature was NMT 45°C. Drying was continued until the Loss on Drying reached in between 2.2 - 3.6 % w/w at 105°C with 3 g sample.
  • the dried granules were milled through 62 G (Grater sieve) using Co-mill at speed of 2500 rpm ⁇ 100 rpm. Before milling the screen impeller distance was adjusted with proper spacer. The milled granules were collected in a double lined LDPE bags (inner clear and outer black) placed inside clean and fared HDPE container labelled with proper status label. The weight was recorded and the containers lid was sealed tightly.
  • Extra granular dispensing the same dispensed quantity of extra granular material was used, if the batch yield of sifted granules was 98.0 % and above. Otherwise, the extra granular material was dispensed based on the batch yield of sifted granules, if the batch yield was less than 98. 0 %.
  • Colloidal silica Aerosil 200 was sifted through #20 mesh and Magnesium Stearate was sifted through #40 mesh by using vibratory sifter and collected separately in a double lined polythene bag in a container.
  • Pre-lubrication the half-sized granules quantity was added into the blender and sifted Colloidal silica Aerosil 200. The remaining half quantity of sized granules were added and blend for 4 mins at 12 rpm.
  • Lubrication the sifted Magnesium Stearate was added into the blender and mixed for 3 mins at 12 rpm. The final blend was collected in double-lined (inner clear & outer black) LDPE bags placed inside a clean and fared HDPE container. Compression stage: the final blend was compressed into the tablets by using a compression machine.
  • Coating stage Purified Water was collected in a clean, dry Stainless Steel vessel. Opadry TF 265F280007-CN was added under stirring condition and after addition, the stirring process was continued for 15 minutes. Dydrogesterone was slowly added into this dispersion under stirring condition. The stirring process was continued after addition for 60 minutes. The suspension was filtered through #100 mesh and the suspension weight after filtration was noted down. The compressed tablets were coated by using 36-inch coating pan.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition à libération modifiée comprenant de la dydrogestérone ou un sel pharmaceutiquement acceptable de celle-ci; et un ou plusieurs polymères régulateurs de libération.
PCT/EP2024/083905 2023-11-30 2024-11-28 Composition à libération modifiée Pending WO2025114430A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23213463.5 2023-11-30
EP23213463 2023-11-30

Publications (1)

Publication Number Publication Date
WO2025114430A1 true WO2025114430A1 (fr) 2025-06-05

Family

ID=89029735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/083905 Pending WO2025114430A1 (fr) 2023-11-30 2024-11-28 Composition à libération modifiée

Country Status (1)

Country Link
WO (1) WO2025114430A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023047274A1 (fr) * 2021-09-24 2023-03-30 Mankind Pharma Ltd. Compositions pharmaceutiques à libération prolongée de dydrogestérone
IN202221071152A (en) * 2022-12-09 2023-11-17 Zydus Lifesciences Limited Extended-release pharmaceutical compositions of dydrogestrone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023047274A1 (fr) * 2021-09-24 2023-03-30 Mankind Pharma Ltd. Compositions pharmaceutiques à libération prolongée de dydrogestérone
IN202221071152A (en) * 2022-12-09 2023-11-17 Zydus Lifesciences Limited Extended-release pharmaceutical compositions of dydrogestrone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.

Similar Documents

Publication Publication Date Title
KR101353736B1 (ko) 유기 화합물의 갈레닉 제제
JP4688089B2 (ja) 放出制御医薬組成物
HRP20250258T1 (hr) Farmaceutska kombinacija, pripravak, i kombinirana priprema koja sadrži aktivator glukokinaze i inhibitor dpp-iv te metode pripreme, i njihova uporaba
DK2400954T3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
EP2468361B1 (fr) Formulations de vildagliptine
JP2008509192A (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
CN101932241A (zh) 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
RU2580652C2 (ru) Фармацевтическая композиция для орального введения
JPWO2014034860A1 (ja) 経口投与用医薬組成物
JP2023513249A (ja) オメカムチブメカルビル製剤
JP2017078023A (ja) 経口投与用医薬組成物
JP2015500853A (ja) 即時放出マルチユニットペレットシステム
JP2017523149A (ja) エドキサバンの医薬組成物
EP2853257B1 (fr) Formulations pharmaceutiques de linagliptine
CA2654872A1 (fr) Formes galeniques associant aliskirene et hydrochlorothiazide
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
WO2025114430A1 (fr) Composition à libération modifiée
US11918692B2 (en) Pharmaceutical compositions
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
EP3335702A1 (fr) Compositions pharmaceutiques comprenant de l'omarigliptine
TWI878600B (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
KR20170113463A (ko) 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제
CA3237792A1 (fr) Composition pharmaceutique presentant d'excellentes caracteristiques de dissolution
JP5321454B2 (ja) 医薬錠剤の製造法
WO2022117594A1 (fr) Préparation administrée par voie orale contenant de la solifénacine et de la tamsulosine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24816753

Country of ref document: EP

Kind code of ref document: A1